key: cord-0738530-5jy5t83b authors: Ghosh, Ritwik; Dubey, Souvik; Sarkar, Anupam; Biswas, Dipankar; Ray, Adrija; Roy, Dipayan; Chatterjee, Subhankar; Benito-Leon, Julian title: Antithyroid arthritis syndrome in a case of post-COVID-19 subacute thyroiditis date: 2021-03-25 journal: Diabetes Metab Syndr DOI: 10.1016/j.dsx.2021.03.015 sha: 0652f8247b4528caeb7fe6ee1e7b27ead12bbf08 doc_id: 738530 cord_uid: 5jy5t83b nan Albeit primarily a disease of the respiratory tract, the coronavirus infectious disease 2019 has causal associations with multiple endocrine complications. 1 Specifically, post-COVID-19 thyroid dysfunctions, including thyrotoxicosis or thyroiditis, are increasingly being reported. [2] [3] [4] [5] [6] Antithyroid arthritis syndrome (AAS) is an under-recognized entity, which occurs within 8 weeks of initiation of antithyroid drugs (either propylthiouracil or carbimazole/methimazole). [7] [8] [9] Clinical spectrum of AAS includes arthralgia, arthritis, myalgia, fever and rash. [7] [8] [9] It is an immune-mediated idiosyncratic adverse drug reaction, which resolves following the withdrawal of the offending drug. [7] [8] [9] However, the clinical picture may persist for years when misdiagnosed as either connective tissue disorders (CTD) or anti-neutrophil cytoplasmic antibodies (ANCA)-positive vasculitides. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] We herein report a non-comorbid man with additive inflammatory polyarthritis after the inapt introduction of carbimazole to manage post-COVID-19 subacute thyroiditis. After revising clinical history and with relevant tests, a final diagnosis of AAS was established. Cessation of carbimazole prompted the disappearance of symptoms. A 50-year-old previously healthy Indian male presented with complaints of acute onset progressive intense pain and swelling in his feet, ankles, wrists, thumbs and J o u r n a l P r e -p r o o f fingers for 1 week. He also complained of continuous low-grade fever for the last three days, which was not associated with any other systemic symptoms except arthralgia. He had been recently treated for COVID-19. After discharge, he complained of irritability, restlessness, malaise, weakness, heat intolerance, diarrhea, sweating, tremulousness and subtle pain in front of his throat for which he consulted multiple physicians. Finally, he was diagnosed with hyperthyroidism and put on carbimazole (30 mg/day). Over the next two weeks, symptoms gradually abated until recently when he came with crippling polyarthritis and fever. Other personal, family and addiction history were unremarkable. General physical examination was remarkable for fever (37.9 ºC) and tachycardia. Systemic examination suggested asymmetric inflammatory arthritis involving peripheral small, medium and large joints, enthesitis, fasciitis and Achilles' tendinitis ( Figure 1 ) without the involvement of axial-joints. Joint deformity, malar/discoid rash, photosensitivity, alopecia, Raynaud's phenomenon, uveitis, mucosal ulcerations, keratoderma blenorrhagicum, vasculitic rashes, lymphadenopathy, goiter, exophthalmos, weight loss, balanitis, urethritis and organomegaly were absent. Keeping post-COVID-19 triggering of CTD associated with dysthyroidism as a working diagnosis, he was put on acetaminophen (2. investigations, a list of differential diagnoses was considered (Table 1) . After a two-week-follow-up, his symptoms substantially reduced. He was put on levothyroxine supplementation (37.5 mcg/day) for correction of hypothyroidism. In the sixth week of follow-up, he had no residual symptoms and levothyroxine requirement was reduced (12.5 mcg/day). Subsequently, in the tenth week of follow-up, levothyroxine was stopped. At the 18th week of follow-up, a drug-free euthyroid state (recovery phase of subacute thyroiditis) was established. Figure 2 summarizes the timeline of events. The entire hypothalamo-pituitary-thyroid axis and the thyroid gland, in particular, may be affected by the SARS-CoV-2 via ACE-2 receptor and TMPRSS2 mediated entry We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome. We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us. We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property. We further confirm that any aspect of the work covered in this manuscript that has involved either experimental animals or human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript. We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). He is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author and which has been configured to accept email from (jbenitol67@gmail.com). Signed on behalf of all authors as follows: Dr. Julián Benito-León COVID-19: the endocrine opportunity in a pandemic Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis Subacute thyroiditis in a patient infected with SARS-COV-2: an endocrine complication linked to the COVID-19 pandemic Subacute thyroiditis associated with COVID-19 Impact of COVID-19 on the thyroid gland: an update Thyrotoxicosis in patients with COVID-19: the THYRCOV study Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-2002. A 21-year-old man with arthritis during treatment for hyperthyroidism Antithyroid arthritis syndrome Antithyroid Arthritis Syndrome: A Case Report and Review of the Literature Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis Antithyroid drugs Clinical study of renal impairment in patients with propylthiouracilinduced small-vessel vasculitis and patients with primary ANCA-associated small-vessel vasculitis Propylthiouracil-induced autoimmune syndromes: two distinct clinical presentations with different course and management Lupus nephritis with positive myeloperoxidase/proteinase 3-antineutrophil cytoplasmic autoantibody that developed after 17 years of propylthiouracil therapy Carbimazole-induced lupus Methimazole-induced lupus erythematosus: a case report Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues A case of methimazole-induced chronic arthritis masquerading as seronegative rheumatoid arthritis Intermittent polyarthritis due to propylthiouracil